Page last updated: 2024-11-07

r 56865

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

R 56865: prevents electrical & mechanical signs of ouabain intoxication in guinea pig papillary muscle [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108043
CHEMBL ID137009
SCHEMBL ID933977
MeSH IDM0153994

Synonyms (19)

Synonym
r 56865
brn 6616961
2-benzothiazolamine, n-(1-(4-(4-fluorophenoxy)butyl)-4-piperidinyl)-n-methyl-
r-56865
r56865
n-(1-(4-(4-fluorophenoxy)butyl)-4-piperidinyl)-n-methyl-2-benzothiazolamine
CHEMBL137009 ,
benzothiazol-2-yl-{1-[4-(4-fluoro-phenoxy)-butyl]-piperidin-4-yl}-methyl-amine
bdbm50067625
n-[1-[4-(4-fluorophenoxy)butyl]piperidin-4-yl]-n-methyl-1,3-benzothiazol-2-amine
104606-13-5
unii-8muq2u7uv6
8muq2u7uv6 ,
2-benzothiazolamine,n-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-n-methyl-
SCHEMBL933977
DTXSID40146613
n-(1-(4-(4-fluorophenoxy)butyl)piperidin-4-yl)-n-methylbenzo[d]thiazol-2-amine
Q27270762
AKOS040747331

Research Excerpts

Overview

R 56865 is an experimental compound that has been shown to ameliorate the effects of cardiac glycoside toxicity and myocardial ischemia.

ExcerptReferenceRelevance
"R 56865 is an experimental compound that has been shown to ameliorate the effects of cardiac glycoside toxicity and myocardial ischemia. "( Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity.
Damiano, BP; Stump, GL; Yagel, SK, 1991
)
1.95

Treatment

ExcerptReferenceRelevance
"Pretreatment with R 56865 (1 mumol l-1) did not counteract the ATX II-induced prolongation of the action potential."( Characterization of the interaction of R 56865 with cardiac Na- and L-type Ca channels.
Himmel, H; Peters, T; Ravens, U; Wilhelm, D, 1991
)
0.87

Toxicity

ExcerptReferenceRelevance
" In Purkinje fibers exposed to toxic concentrations of ouabain, R 56865 (1 microM) reduced the delayed after depolarization (DAD) amplitude and inhibited triggered activity."( Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity.
Damiano, BP; Stump, GL; Yagel, SK, 1991
)
0.75

Dosage Studied

ExcerptRelevanceReference
" The absence of a depression of the maximum of the dose-response curve of ST 587 and the very moderate attenuation of the maximal B-HT 920-induced increase in diastolic blood pressure (BP) confirms the lack of major calcium entry blocking properties of R 56865 for alpha-adrenoceptor-activated calcium channels in vitro."( Interaction between R 56865 and alpha-adrenoceptors in the pithed rat.
Fruh, C; Koch, P; Peters, T; Schneider, J; Wilffert, B; Wilhelm, D,
)
0.64
" The antiischemic and antiarrhythmic dose-response curves were superimposable, suggesting a common mechanism of action."( Attenuation by R 56865, a novel cytoprotective drug, of regional myocardial ischemia- and reperfusion-induced electrocardiographic disturbances in anesthetized rabbits.
De Courtois, F; John, GW; Le Grand, B; Pouget, G; Verscheure, Y, 1995
)
0.64
" R56865 was given before ischemia and with the onset of reperfusion, applying different dosing schedules, including an initial loading dose."( R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion.
Guttmann, I; Mozes, A; Scheufler, E; Wilffert, B, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID195587In vitro inhibition of veratridine induced rat myocardiac cell death.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)thiazolidinones.
AID180514In vitro inhibition of K+ induced contractions of the isolated rat aorta.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)thiazolidinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.63)18.7374
1990's64 (90.14)18.2507
2000's3 (4.23)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.38 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.68 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.39%)5.53%
Reviews3 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]